Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples